Bristol Myers Squibb's Sotyktu Approved for Psoriatic Arthritis Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 07 2026
0mins
Should l Buy BMY?
Source: Benzinga
- New Drug Approval: Bristol Myers Squibb's oral drug Sotyktu has received FDA approval for treating adults with active psoriatic arthritis, providing a new treatment option for alleviating joint and skin symptoms.
- Clinical Trial Results: In two global Phase 3 studies, 54% of patients taking Sotyktu achieved an ACR20 response by Week 16, compared to only 34% and 39% in the placebo groups, demonstrating significant treatment efficacy.
- Safety Profile: The drug's safety profile is similar to earlier psoriasis studies, with common side effects including respiratory infections and mouth ulcers; the FDA mandates tuberculosis screening before treatment to mitigate infection risks.
- Market Impact: This approval underscores Sotyktu's critical role in managing psoriatic arthritis, potentially enhancing Bristol Myers Squibb's position in the immunology market and driving further development in immune-related diseases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BMY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BMY
Wall Street analysts forecast BMY stock price to fall
20 Analyst Rating
8 Buy
11 Hold
1 Sell
Moderate Buy
Current: 57.590
Low
37.00
Averages
55.86
High
68.00
Current: 57.590
Low
37.00
Averages
55.86
High
68.00
About BMY
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development, and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Orencia (abatacept), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Breyanzi (lisocabtagene maraleucel), Opdualag (nivolumab and relatlimab-rmbw), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), Sotyktu (deucravacitinib), Krazati (adagrasib), and Cobenfy (xanomeline and trospium chloride). Its other growth products include Augtyro, Onureg, Inrebic, Nulojix, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bristol-Myers Squibb Q1 2026 Earnings Call Highlights
- Solid Financial Performance: Bristol-Myers Squibb reported a 1% year-over-year increase in total revenue for Q1 2026, reaching approximately $11.5 billion, while diluted earnings per share stood at $1.58, reflecting the company's stability and ongoing profitability in the market.
- Strong Growth Portfolio: The company's growth portfolio sales rose by 9% year-over-year to $6.2 billion, indicating sustained demand for key product lines and enhancing its competitive position in the pharmaceutical industry.
- Significant R&D Progress: The FDA accepted the filing for iberdomide for relapsed or refractory multiple myeloma with breakthrough therapy designation, with a PDUFA date set for August 17, which will provide crucial support for the company's future product line expansion.
- Positive Future Outlook: Management reaffirmed its financial guidance for 2026, anticipating multiple pivotal readouts in the second half of the year, including results from milvexian and Cobenfy clinical trials, which could drive potential growth and bolster investor confidence.
See More
Bristol Myers Squibb Reports Strong Q1 Performance
- Performance Growth Driver: Bristol Myers Squibb's Q1 revenue rose 3% year-over-year to $11.5 billion, primarily driven by a 12% sales increase in its growth portfolio, contributing $6.2 billion, which reflects the company's strong performance in new drug development and boosts investor confidence.
- Earnings Beat Expectations: Despite a decline in non-GAAP net income to $3.2 billion ($1.58 per share), the results exceeded analyst expectations of $1.42 per share, indicating the company's resilience in profitability and reinforcing market confidence in its future prospects.
- Product Portfolio Performance: Every drug in the growth portfolio, except for cancer treatment Opdivo, saw year-over-year sales increases, while the legacy portfolio experienced a 6% decline, highlighting the company's competitive advantage and market potential in emerging therapeutic areas.
- Future Outlook: Bristol Myers Squibb reaffirmed its guidance for 2026, projecting total revenue between $46 billion and $47.5 billion, with adjusted earnings per share forecasted at $6.05 to $6.35, aligning with average analyst projections, indicating the company's growth potential and stability moving forward.
See More
Bristol-Myers Squibb Q1 Earnings Beat Expectations
- Strong Financial Performance: Bristol-Myers Squibb reported $11.5 billion in revenue for Q1 2026, reflecting a ~3% year-over-year growth that exceeded market expectations by $580 million, demonstrating the company's financial resilience amid challenges.
- Growth Portfolio Outperformance: The growth portfolio contributed $6.2 billion in revenue with ~12% year-over-year growth, driven by cancer therapy Opdivo and rheumatoid arthritis drug Orencia generating $2.1 billion and $818 million, respectively, indicating strong market acceptance of new product lines.
- Legacy Product Decline: Despite the strong performance of the growth portfolio, the legacy product line contracted ~6% year-over-year, generating $5.3 billion, highlighting the impact of generics on other products and the need for a faster transition to maintain competitive positioning.
- Reaffirmed Full-Year Outlook: The company reaffirmed its full-year revenue guidance of $46.0 billion to $47.5 billion and adjusted EPS of $6.05 to $6.35, aligning with market consensus, reflecting management's confidence in future performance.
See More
Bristol-Myers Squibb Exceeds Earnings Expectations
- Strong Earnings Report: Bristol-Myers Squibb reported a non-GAAP EPS of $1.58 for Q1, surpassing expectations by $0.16, which demonstrates robust profitability and boosts investor confidence.
- Revenue Growth: The company achieved $11.5 billion in revenue for the first quarter, exceeding forecasts by $580 million, indicating sustained growth in its product portfolio and reinforcing its market position.
- Growth Potential: Despite facing patent expiration challenges, Bristol-Myers Squibb's growth portfolio remains undervalued by the market, with analysts suggesting that upcoming milestones could significantly enhance the company's prospects.
- Market Reaction: The better-than-expected earnings report may prompt investors to reassess the stock's value, likely resulting in a positive impact on the share price and further enhancing the company's competitiveness in the biopharmaceutical sector.
See More
Alphabet CEO Highlights Significant AI Investment Payoff
- Earnings Beat Expectations: Alphabet's Q1 earnings report revealed a 63% year-over-year increase in cloud revenue and an 81% rise in net income, with CEO Sundar Pichai stating that the full-stack approach to AI investments is driving strong performance.
- Consumer Subscription Surge: The adoption of the Gemini app reached an all-time high, indicating robust demand for consumer subscription AI plans, with analyst Sanmeet Deo noting that Alphabet's substantial investments in AI are translating into impressive financial returns, boosting investor confidence.
- Positive Market Reaction: Ahead of the earnings release, Alphabet's stock surged over 7%, reflecting investor optimism about the company's future, particularly its potential to dominate the AI revolution.
- Clear Strategic Positioning: Analysts believe that Alphabet's AI investments not only enhance current performance but also lay the groundwork for future market competition, ensuring the company's leadership in the rapidly evolving AI landscape.
See More
Bristol Myers Squibb Reports Q1 2026 Financial Results
- Earnings Release: Bristol Myers Squibb reported its Q1 2026 financial results on April 30, 2026, highlighting the company's ongoing commitment to innovative drug development, although specific financial metrics have yet to be disclosed, keeping the market attentive to its future performance.
- Investor Call: The company will host a conference call for analysts and investors at 8:00 a.m. ET on the same day as the earnings release, where executives are expected to discuss financial results and future outlook, enhancing communication with investors.
- Webcast Replay: A replay of the earnings call will be available approximately three hours after the conclusion of the meeting on the company's Investor Relations website, ensuring that investors who could not participate live can access key information.
- Corporate Mission: Bristol Myers Squibb is dedicated to transforming patients' lives through science, focusing on discovering, developing, and delivering innovative medicines to help patients overcome serious diseases, showcasing its strategic positioning in the biopharmaceutical sector.
See More
Bristol-Myers Squibb Q1 2026 Earnings Call Highlights
- Solid Financial Performance: Bristol-Myers Squibb reported a 1% year-over-year increase in total revenue for Q1 2026, reaching approximately $11.5 billion, while diluted earnings per share stood at $1.58, reflecting the company's stability and ongoing profitability in the market.
- Strong Growth Portfolio: The company's growth portfolio sales rose by 9% year-over-year to $6.2 billion, indicating sustained demand for key product lines and enhancing its competitive position in the pharmaceutical industry.
- Significant R&D Progress: The FDA accepted the filing for iberdomide for relapsed or refractory multiple myeloma with breakthrough therapy designation, with a PDUFA date set for August 17, which will provide crucial support for the company's future product line expansion.
- Positive Future Outlook: Management reaffirmed its financial guidance for 2026, anticipating multiple pivotal readouts in the second half of the year, including results from milvexian and Cobenfy clinical trials, which could drive potential growth and bolster investor confidence.
See More
Bristol Myers Squibb Reports Strong Q1 Performance
- Performance Growth Driver: Bristol Myers Squibb's Q1 revenue rose 3% year-over-year to $11.5 billion, primarily driven by a 12% sales increase in its growth portfolio, contributing $6.2 billion, which reflects the company's strong performance in new drug development and boosts investor confidence.
- Earnings Beat Expectations: Despite a decline in non-GAAP net income to $3.2 billion ($1.58 per share), the results exceeded analyst expectations of $1.42 per share, indicating the company's resilience in profitability and reinforcing market confidence in its future prospects.
- Product Portfolio Performance: Every drug in the growth portfolio, except for cancer treatment Opdivo, saw year-over-year sales increases, while the legacy portfolio experienced a 6% decline, highlighting the company's competitive advantage and market potential in emerging therapeutic areas.
- Future Outlook: Bristol Myers Squibb reaffirmed its guidance for 2026, projecting total revenue between $46 billion and $47.5 billion, with adjusted earnings per share forecasted at $6.05 to $6.35, aligning with average analyst projections, indicating the company's growth potential and stability moving forward.
See More
Bristol-Myers Squibb Q1 Earnings Beat Expectations
- Strong Financial Performance: Bristol-Myers Squibb reported $11.5 billion in revenue for Q1 2026, reflecting a ~3% year-over-year growth that exceeded market expectations by $580 million, demonstrating the company's financial resilience amid challenges.
- Growth Portfolio Outperformance: The growth portfolio contributed $6.2 billion in revenue with ~12% year-over-year growth, driven by cancer therapy Opdivo and rheumatoid arthritis drug Orencia generating $2.1 billion and $818 million, respectively, indicating strong market acceptance of new product lines.
- Legacy Product Decline: Despite the strong performance of the growth portfolio, the legacy product line contracted ~6% year-over-year, generating $5.3 billion, highlighting the impact of generics on other products and the need for a faster transition to maintain competitive positioning.
- Reaffirmed Full-Year Outlook: The company reaffirmed its full-year revenue guidance of $46.0 billion to $47.5 billion and adjusted EPS of $6.05 to $6.35, aligning with market consensus, reflecting management's confidence in future performance.
See More
Bristol-Myers Squibb Exceeds Earnings Expectations
- Strong Earnings Report: Bristol-Myers Squibb reported a non-GAAP EPS of $1.58 for Q1, surpassing expectations by $0.16, which demonstrates robust profitability and boosts investor confidence.
- Revenue Growth: The company achieved $11.5 billion in revenue for the first quarter, exceeding forecasts by $580 million, indicating sustained growth in its product portfolio and reinforcing its market position.
- Growth Potential: Despite facing patent expiration challenges, Bristol-Myers Squibb's growth portfolio remains undervalued by the market, with analysts suggesting that upcoming milestones could significantly enhance the company's prospects.
- Market Reaction: The better-than-expected earnings report may prompt investors to reassess the stock's value, likely resulting in a positive impact on the share price and further enhancing the company's competitiveness in the biopharmaceutical sector.
See More
Alphabet CEO Highlights Significant AI Investment Payoff
- Earnings Beat Expectations: Alphabet's Q1 earnings report revealed a 63% year-over-year increase in cloud revenue and an 81% rise in net income, with CEO Sundar Pichai stating that the full-stack approach to AI investments is driving strong performance.
- Consumer Subscription Surge: The adoption of the Gemini app reached an all-time high, indicating robust demand for consumer subscription AI plans, with analyst Sanmeet Deo noting that Alphabet's substantial investments in AI are translating into impressive financial returns, boosting investor confidence.
- Positive Market Reaction: Ahead of the earnings release, Alphabet's stock surged over 7%, reflecting investor optimism about the company's future, particularly its potential to dominate the AI revolution.
- Clear Strategic Positioning: Analysts believe that Alphabet's AI investments not only enhance current performance but also lay the groundwork for future market competition, ensuring the company's leadership in the rapidly evolving AI landscape.
See More
Bristol Myers Squibb Reports Q1 2026 Financial Results
- Earnings Release: Bristol Myers Squibb reported its Q1 2026 financial results on April 30, 2026, highlighting the company's ongoing commitment to innovative drug development, although specific financial metrics have yet to be disclosed, keeping the market attentive to its future performance.
- Investor Call: The company will host a conference call for analysts and investors at 8:00 a.m. ET on the same day as the earnings release, where executives are expected to discuss financial results and future outlook, enhancing communication with investors.
- Webcast Replay: A replay of the earnings call will be available approximately three hours after the conclusion of the meeting on the company's Investor Relations website, ensuring that investors who could not participate live can access key information.
- Corporate Mission: Bristol Myers Squibb is dedicated to transforming patients' lives through science, focusing on discovering, developing, and delivering innovative medicines to help patients overcome serious diseases, showcasing its strategic positioning in the biopharmaceutical sector.
See More
